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fibrinoid or inflammatory changes, and therefore appropriate steroid
therapy to control SLE is quite important to prevent its recurrence. In
other words, mitral valve plasty (particularly in patients without mitral
regurgitation) is thought to be an appropriate option if good control of
SLE is possible. At 6 months after the operation, our patient showed
no evidence of recurrence on echocardiography.
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Giant cell aortitis with histopathologic and clinical response to steroid
therapy: A case report
Howard Blumstein, MD,a Leslie Dubin Kerr, MD,a and John T. Fallon, MD, PhD,b New York, NY
Giant cell arteritis (GCA) is a large-vessel vasculitisthat affects older individuals and typically presentswith constitutional symptoms, polymyalgia, head-ache, scalp tenderness, jaw claudication, or sudden
vision loss.1
A subset of patients with GCA can present with large artery
disease consisting of aortic aneurysm, dissection, or both.2 We
have also recently described our own experience with 19 such
patients who underwent surgical repair of aortic aneurysms and
who were found to have unsuspected giant cell aortitis on his-
topathologic review.3 This study suggested that large-vessel giant
cell aortitis might be a different disease from classic GCA because
of its unusual clinical presentation. No conclusions, however,
could be drawn regarding the effectiveness of subsequent steroid
therapy for this variant of the disease.
A unique opportunity to explore this question arose when a
patient with 2 known aortic aneurysms presented. Giant cell aor-
titis was documented at the repair of the first aneurysm. This patient
subsequently lost vision and hearing and regained both after steroid
therapy. When the second repair was performed 14 months later,
the histopathologic effect of steroid treatment was assessed.
Clinical Summary
A 67-year-old woman in whom 2 large aneurysms, a thoracic and
a thoracoabdominal aneurysm, had been incidentally found on
computed tomographic scanning was referred for cardiac catheter-
ization and further management. The catheterization demonstrated
severe left main disease, normal left ventricular function, a dilated
aortic root with severe aortic insufficiency, and mild narrowing of
the right subclavian artery. The patient then underwent a stage I
Bentall procedure with osteoplasty of the left main coronary artery.
The repair of the thoracoabdominal aneurysm was deferred. On
postoperative day 2, she experienced sudden loss of vision in her
left eye. The pathology report documented the presence of active
giant cell aortitis, and rheumatology consultation was requested.
On initial evaluation, the patient denied antecedent symptoms of
polymyalgia, headache, scalp tenderness, jaw claudication, joint
pains, or constitutional symptoms. She described her vision loss as
sudden and accompanied by decreased hearing.
On physical examination, she had no scalp or temporal
artery tenderness, and no bruits were appreciated. There was no
evidence of synovitis or muscle tenderness. Visual acuity was
markedly reduced, and hearing was diminished. Her sedimen-
tation rate was 31 mm/h (Westergren). Treatment with high-
dose intravenous steroids (dexamethasone, 4.5 mg every 12
hours) was begun. Over the next 2 weeks, her vision improved
only marginally, and the steroids were then tapered to 5 mg/d.
This dose was continued, and at 1 month postoperatively, the
patient suddenly regained vision in her left eye and noted
restoration of hearing. Prednisone, 5 mg/d, was continued for 6
months and then discontinued. Fourteen months after the initial
repair, the patient then underwent repair of the remaining
thoracoabdominal aneurysm. This specimen demonstrated se-
vere atherosclerotic changes with mural thrombus; no evidence
of discrete aortitis was seen. The patient had an uneventful
hospital course and was discharged without steroid therapy.
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Methods
The surgical specimens from both procedures were fixed in for-
malin, paraffin embedded, and stained with hematoxylin and eosin.
Results
Figure 1, A (2) and B (10), depicts the initial thoracic aortic
biopsy. This specimen demonstrates active giant cell aortitis.
There is an abundance of palisading inflammatory cells, including
giant multinucleated cells. The elastic lamina is disrupted by
medial necrosis. Figure 2, A (4) and B (10), shows the second
aortic specimen from the resection of the thoracoabdominal aortic
aneurysm 14 months later. In contrast, this specimen demonstrates
no evidence of active aortitis. Instead, severe atherosclerotic
changes with medial degeneration and a minimal inflammatory
infiltrate are seen, which is consistent with healed aortitis.
Discussion
The literature currently supports the concept that there is a difference
between classic cranial GCA and large-vessel giant cell aortitis.
Brack and colleagues2 described a group of patients with upper
extremity vascular insufficiency and compared these patients
with those with classic cranial GCA. The patients with large-
vessel disease rarely presented with headache, jaw claudication,
or visual impairment. Nuenninghoff and associates4 found a
negative association between cranial symptoms, increased sed-
imentation rate, and large artery complications from aortitis.
Zehr and coworkers5 reported 37 patients with giant cell aorti-
tis, 13 of whom were treated with steroids postoperatively.
Because none of these patients underwent repeat operations, the
effect of this therapy could not be ascertained. Thus no data
exist regarding the steroid responsiveness of this GCA variant.
Thus this case is important because it documents the effect of
steroid therapy on giant cell aortitis. The initial biopsy specimen
demonstrated active giant cell aortitis. In contrast, the second biopsy
specimen obtained after prolonged steroid therapy had no evi-
dence of active disease. Healed aortitis pathologically corre-
lated with clinical improvement. Although these data are limited to
one patient, it suggests that large-vessel giant cell aortitis is quite
steroid responsive. This histopathologic improvement combined
with a dramatically improved clinical outcome underscores the
benefits of prompt recognition and treatment of giant cell aortitis.
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Figure 1. Thoracic aneurysm before therapy.
Figure 2. Thoracoabdominal aneurysm after steroid therapy.
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